THOUSAND OAKS, Calif.,
March 18, 2017 /PRNewswire/ -- Amgen
(NASDAQ:AMGN) today announced detailed results from the
Repatha® (evolocumab) cognitive function trial
(EBBINGHAUS) evaluating the impact on cognitive function in 1,974
patients enrolled in the Repatha cardiovascular outcomes study
(FOURIER). The study demonstrated that the effect of Repatha on the
primary endpoint of executive function was non-inferior to placebo.
In addition, there was no statistical difference between Repatha
and placebo on the other cognitive domains tested: working memory,
memory function and psychomotor speed (secondary endpoints). The
detailed results from EBBINGHAUS were presented at a Late-Breaking
Clinical Trials Session at the American College of Cardiology
66th Annual Scientific Session (ACC.17) in Washington, D.C.
"There has long been a debate that low LDL cholesterol levels
could lead to negative effects on memory or other cognitive
functions," said Robert P.
Giugliano, M.D., S.M., Brigham and Women's Hospital,
Boston and lead study
investigator. "We did not find evidence for a decline in
neurocognitive function after nearly two years of treatment with
evolocumab using a dedicated series of neuropsychologic tests. We
also asked patients and their physicians to provide their
assessments and found no differences between evolocumab and
placebo. These findings provide strong support for the safety of
reducing LDL with evolocumab to levels well below current treatment
targets."
In the primary cohort of 1,204 patients, followed for a median
of 19 months, the change from baseline raw score of spatial working
memory strategy index of executive function was similar in the
Repatha and placebo groups (mean baseline score 17.8; mean change
from baseline -0.2 versus -0.3, respectively). The primary
endpoint was below the pre-specified margin, demonstrating
non-inferiority. The primary endpoint was assessed by the Cambridge
Neuropsychological Test Automated Battery (CANTAB) Spatial Working
Memory strategy index of executive function, an established
language- and culture-independent computerized, tablet-based
cognitive assessment tool.
"These results, from one of the largest randomized controlled
trials on cognitive function, clearly demonstrated that lowering
LDL-C to unprecedented levels with Repatha did not negatively
impact cognition," said Sean E.
Harper, M.D., executive vice president of Research and
Development at Amgen. "These results further support the safety of
Repatha as an effective LDL-lowering therapy with no observed
negative effects on memory or other cognitive functions."
Secondary endpoint results in the three cognitive domains of
working memory, memory function and psychomotor speed were
consistent with the primary endpoint result. Patients treated with
Repatha experienced change from baseline similar to placebo in all
three cognitive domains tested: spatial working memory
between-errors score (baseline 21.0, Repatha -0.5 versus placebo
-0.9), paired associates learning total errors adjusted (baseline
25.8, change with Repatha -1.5 versus -1.5 with placebo), RTI
median five-choice reaction time (baseline 355.9, 5.2 milliseconds
change with Repatha versus 0.9 milliseconds with placebo). Changes
from baseline in the global composite score were similar between
treatment arms (baseline -0.008, changes with Repatha 0.03 versus
0.06 with placebo). Results in the full cohort were consistent with
those in the primary cohort.
In an exploratory analysis, these results were consistent
regardless of achieved low-density lipoprotein cholesterol (LDL-C)
levels, including 661 patients with the lowest LDL-C level (<25
mg/dL).
In the EBBINGHAUS study, neurocognitive adverse event rates were
similar between treatment arms. In the full cohort, 19 (1.9
percent) neurocognitive adverse events were reported in the Repatha
group compared to 16 (1.6 percent) events in the placebo group. In
the 27,564-patient Repatha cardiovascular outcomes trial (FOURIER),
neurocognitive adverse events were reported in 1.6 percent in the
Repatha group compared to 1.5 percent in the placebo group. The
adverse events identified in EBBINGHAUS were consistent with the
adverse events identified in FOURIER.
Repatha Cognitive Function (EBBINGHAUS) Study Design
EBBINGHAUS (Evaluating PCSK9 Binding antiBody Influence oN
coGnitive HeAlth in high cardiovascUlar risk Subjects) is a
double-blind, placebo-controlled randomized non-inferiority trial
involving of 1,974 patients with clinically evident atherosclerotic
cardiovascular disease enrolled in the Repatha cardiovascular
outcomes trial (FOURIER). The primary non-inferiority assessment of
the primary endpoint spatial working memory strategy index of
executive function (assessing executive function, or high-level
thinking and decision making) was performed on the primary cohort
of 1,204 patients who enrolled on or before the first dose of
investigational product and had at least one post-baseline CANTAB
assessment. The full cohort (1,974 patients) included all
randomized patients. The primary endpoint was assessed by comparing
the 95 percent confidence interval (CI) with the pre-specified
non-inferiority margin for the treatment difference between Repatha
and placebo. Secondary endpoints were the CANTAB Spatial Working
Memory between-errors score (assessing working memory, or the
ability to hold material in mind while that material is being
actively processed); the CANTAB Paired Associates Learning Total
Errors Adjusted (assessing memory function, or the ability to store
and retrieve information by associating an event with a time and
place); and the CANTAB Reaction Time Five-Choice Median Reaction
Time (assessing psychomotor speed, which is responsible for
detecting and responding to a stimulus). For all three secondary
endpoints, the 95 percent CI for the estimated treatment difference
between Repatha and placebo spanned equivalence.
Primary and secondary endpoints were assessed using a
tablet-based tool at baseline, weeks 24, yearly, and at study end.
The primary analysis compared the mean change from baseline in
patients who had a baseline cognitive assessment on or prior to the
first day of study drug.
Repatha Cardiovascular Outcomes (FOURIER) Study
Design
FOURIER (Further
Cardiovascular OUtcomes Research with
PCSK9 Inhibition in Subjects with Elevated Risk), a
multinational Phase 3 randomized, double-blind, placebo-controlled
trial, is designed to evaluate whether treatment with Repatha in
combination with statin therapy compared to placebo plus statin
therapy reduces cardiovascular events. The hard major adverse
cardiovascular event (MACE) composite endpoint is the time to
cardiovascular death, myocardial infarction or stroke (key
secondary endpoint). The extended MACE composite endpoint is the
time to cardiovascular death, myocardial infarction, stroke,
hospitalization for unstable angina, or coronary revascularization
(primary endpoint).
Eligible patients with high cholesterol (LDL-C ≥70 mg/dL or
non-high-density lipoprotein cholesterol [non-HDL-C] ≥100 mg/dL)
and clinically evident atherosclerotic cardiovascular disease at
more than 1,300 study locations around the world were randomized to
receive Repatha subcutaneous 140 mg every two weeks or 420 mg
monthly plus effective statin dose; or placebo subcutaneous every
two weeks or monthly plus effective statin dose. Optimized statin
therapy was defined as at least atorvastatin 20 mg or equivalent
daily with a recommendation for at least atorvastatin 40 mg or
equivalent daily where approved. The study was event driven and
continued until at least 1,630 patients experienced a key secondary
endpoint.
About
Repatha® (evolocumab)
Repatha® (evolocumab)
is a human monoclonal antibody that inhibits proprotein convertase
subtilisin/kexin type 9 (PCSK9). Repatha binds to PCSK9 and
inhibits circulating PCSK9 from binding to the low-density
lipoprotein (LDL) receptor (LDLR), preventing PCSK9-mediated LDLR
degradation and permitting LDLR to recycle back to the liver cell
surface. By inhibiting the binding of PCSK9 to LDLR, Repatha
increases the number of LDLRs available to clear LDL from the
blood, thereby lowering LDL-C levels.1
Repatha is approved in more than 40 countries, including the
U.S., Japan, Canada and in all 28 countries that are
members of the European Union. Applications in other countries
are pending.
U.S. Repatha Indication
Repatha® is
indicated as an adjunct to diet and:
- Maximally tolerated statin therapy for treatment of adults with
heterozygous familial hypercholesterolemia (HeFH) or clinical
atherosclerotic cardiovascular disease (ASCVD), who require
additional lowering of low-density lipoprotein cholesterol
(LDL-C)
- Other LDL-lowering therapies (e.g., statins, ezetimibe, LDL
apheresis) in patients with homozygous familial
hypercholesterolemia (HoFH) who require additional lowering of
LDL-C
The effect of Repatha® on cardiovascular
morbidity and mortality has not been determined.
The safety and effectiveness of Repatha® have
not been established in pediatric patients with HoFH who are
younger than 13 years old.
The safety and effectiveness of Repatha® have
not been established in pediatric patients with primary
hyperlipidemia or HeFH.
Important U.S. Safety
Information
Contraindication:
Repatha® is contraindicated in patients with a
history of a serious hypersensitivity reaction to
Repatha®.
Allergic reactions: Hypersensitivity reactions (e.g.
rash, urticaria) have been reported in patients treated with
Repatha®, including some that led to discontinuation of
therapy. If signs or symptoms of serious allergic reactions occur,
discontinue treatment with Repatha®, treat according to
the standard of care, and monitor until signs and symptoms
resolve.
Adverse reactions: The most common adverse reactions
(>5% of Repatha®-treated patients and more common
than placebo) were: nasopharyngitis, upper respiratory tract
infection, influenza, back pain, and injection site reactions.
In a 52-week trial, adverse reactions led to discontinuation of
treatment in 2.2% of Repatha®-treated patients and 1% of
placebo-treated patients. The most common adverse reaction that led
to Repatha® treatment discontinuation and occurred
at a rate greater than placebo was myalgia (0.3% versus 0% for
Repatha® and placebo, respectively).
Adverse reactions from a pool of the 52-week trial and seven
12-week trials: Local injection site reactions occurred in 3.2% and
3.0% of Repatha®-treated and placebo-treated patients,
respectively. The most common injection site reactions were
erythema, pain, and bruising. The proportions of patients who
discontinued treatment due to local injection site reactions in
Repatha®-treated patients and placebo-treated patients
were 0.1% and 0%, respectively.
Allergic reactions occurred in 5.1% and 4.7% of
Repatha®-treated and placebo-treated patients,
respectively. The most common allergic reactions were rash (1.0%
versus 0.5% for Repatha® and placebo,
respectively), eczema (0.4% versus 0.2%), erythema (0.4% versus
0.2%), and urticaria (0.4% versus 0.1%).
Neurocognitive events were reported in less than or equal to
0.2% in Repatha®-treated and placebo-treated
patients.
In a pool of placebo- and active-controlled trials, as well as
open-label extension studies that followed them, a total of 1,988
patients treated with Repatha® had at least one
LDL-C value <25 mg/dL. Changes to background lipid-altering
therapy were not made in response to low LDL-C values, and
Repatha® dosing was not modified or interrupted on
this basis. Although adverse consequences of very low LDL-C were
not identified in these trials, the long-term effects of very low
levels of LDL-C induced by Repatha® are
unknown.
Musculoskeletal adverse reactions were reported in 14.3% of
Repatha®-treated patients and 12.8% of placebo-treated
patients. The most common adverse reactions that occurred at a rate
greater than placebo were back pain (3.2% versus 2.9% for
Repatha® and placebo, respectively), arthralgia
(2.3% versus 2.2%), and myalgia (2.0% versus 1.8%).
Homozygous Familial Hypercholesterolemia (HoFH): In
49 patients with homozygous familial hypercholesterolemia studied
in a 12-week, double-blind, randomized, placebo-controlled trial,
33 patients received 420 mg of
Repatha® subcutaneously once monthly. The adverse
reactions that occurred in at least 2 (6.1%)
Repatha®-treated patients and more frequently than in
placebo-treated patients, included upper respiratory tract
infection (9.1% versus 6.3%), influenza (9.1% versus 0%),
gastroenteritis (6.1% versus 0%), and nasopharyngitis (6.1% versus
0%).
Immunogenicity: Repatha® is a human
monoclonal antibody. As with all therapeutic proteins, there is a
potential for immunogenicity with Repatha®.
Please contact Amgen Medinfo at 800-77-AMGEN (800-772-6436)
or 844-REPATHA (844-737-2842) regarding
Repatha® availability or find more information,
including full Prescribing Information,
at www.amgen.com and www.Repatha.com.
About Amgen in the Cardiovascular Therapeutic
Area
Building on more than three decades of experience in
developing biotechnology medicines for patients with serious
illnesses, Amgen is dedicated to addressing important
scientific questions to advance care and improve the lives of
patients with cardiovascular disease, the leading cause of
morbidity and mortality
worldwide.2 Amgen's research into
cardiovascular disease, and potential treatment options, is part of
a growing competency at Amgen that utilizes human
genetics to identify and validate certain drug targets. Through its
own research and development efforts, as well as
partnerships, Amgen is building a robust cardiovascular
portfolio consisting of several approved and investigational
molecules in an effort to address a number of today's important
unmet patient needs, such as high cholesterol and heart
failure.
About Amgen
Amgen is committed to
unlocking the potential of biology for patients suffering from
serious illnesses by discovering, developing, manufacturing and
delivering innovative human therapeutics. This approach begins by
using tools like advanced human genetics to unravel the
complexities of disease and understand the fundamentals of human
biology.
Amgen focuses on areas of high unmet medical need and
leverages its expertise to strive for solutions that improve health
outcomes and dramatically improve people's lives. A biotechnology
pioneer since 1980, Amgen has grown to be one of the
world's leading independent biotechnology companies, has reached
millions of patients around the world and is developing a pipeline
of medicines with breakaway potential.
For more information, visit www.amgen.com and follow
us on www.twitter.com/amgen.
Forward-Looking Statements
This news release contains
forward-looking statements that are based on the current
expectations and beliefs of Amgen. All statements, other than
statements of historical fact, are statements that could be deemed
forward-looking statements, including estimates of revenues,
operating margins, capital expenditures, cash, other financial
metrics, expected legal, arbitration, political, regulatory or
clinical results or practices, customer and prescriber patterns or
practices, reimbursement activities and outcomes and other such
estimates and results. Forward-looking statements involve
significant risks and uncertainties, including those discussed
below and more fully described in the Securities and Exchange
Commission reports filed by Amgen, including our most recent annual
report on Form 10-K and any subsequent periodic reports on Form
10-Q and Form 8-K. Unless otherwise noted, Amgen is providing this
information as of the date of this news release and does not
undertake any obligation to update any forward-looking statements
contained in this document as a result of new information, future
events or otherwise.
No forward-looking statement can be guaranteed and actual
results may differ materially from those we project. Our results
may be affected by our ability to successfully market both new and
existing products domestically and internationally, clinical and
regulatory developments involving current and future products,
sales growth of recently launched products, competition from other
products including biosimilars, difficulties or delays in
manufacturing our products and global economic conditions. In
addition, sales of our products are affected by pricing pressure,
political and public scrutiny and reimbursement policies imposed by
third-party payers, including governments, private insurance plans
and managed care providers and may be affected by regulatory,
clinical and guideline developments and domestic and international
trends toward managed care and healthcare cost containment.
Furthermore, our research, testing, pricing, marketing and other
operations are subject to extensive regulation by domestic and
foreign government regulatory authorities. We or others could
identify safety, side effects or manufacturing problems with our
products after they are on the market. Our business may be impacted
by government investigations, litigation and product liability
claims. In addition, our business may be impacted by the adoption
of new tax legislation or exposure to additional tax liabilities.
If we fail to meet the compliance obligations in the corporate
integrity agreement between us and the U.S. government, we could
become subject to significant sanctions. Further, while we
routinely obtain patents for our products and technology, the
protection offered by our patents and patent applications may be
challenged, invalidated or circumvented by our competitors, or we
may fail to prevail in present and future intellectual property
litigation. We perform a substantial amount of our commercial
manufacturing activities at a few key facilities and also depend on
third parties for a portion of our manufacturing activities, and
limits on supply may constrain sales of certain of our current
products and product candidate development. In addition, we compete
with other companies with respect to many of our marketed products
as well as for the discovery and development of new products.
Discovery or identification of new product candidates cannot be
guaranteed and movement from concept to product is uncertain;
consequently, there can be no guarantee that any particular product
candidate will be successful and become a commercial product.
Further, some raw materials, medical devices and component parts
for our products are supplied by sole third-party suppliers.
Certain of our distributors, customers and payers have substantial
purchasing leverage in their dealings with us. The discovery of
significant problems with a product similar to one of our products
that implicate an entire class of products could have a material
adverse effect on sales of the affected products and on our
business and results of operations. Our efforts to acquire other
companies or products and to integrate the operations of companies
we have acquired may not be successful. We may not be able to
access the capital and credit markets on terms that are favorable
to us, or at all. We are increasingly dependent on information
technology systems, infrastructure and data security. Our stock
price is volatile and may be affected by a number of events. Our
business performance could affect or limit the ability of our Board
of Directors to declare a dividend or our ability to pay a dividend
or repurchase our common stock.
The scientific information discussed in this news release
relating to new indications is preliminary and investigative and is
not part of the labeling approved by the U.S. Food and Drug
Administration or European Commission for the products. The
products are not approved for the investigational use(s) discussed
in this news release, and no conclusions can or should be drawn
regarding the safety or effectiveness of the products for these
uses.
CONTACT: Amgen, Thousand
Oaks
Kristen Davis, 805-447-3008
(Media)
Kristen Neese, 805-313-8267
(Media)
Arvind Sood, 805-447-1060
(Investors)
REFERENCES
- Repatha® U.S. Prescribing
Information. Amgen.
- World Health Organization. Cardiovascular diseases (CVDs) fact
sheet. http://www.who.int/mediacentre/factsheets/fs317/en/.
Accessed February 2017.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lowering-ldl-levels-with-repatha-evolocumab-did-not-adversely-affect-cognitive-function-in-landmark-phase-3-study-300425744.html
SOURCE Amgen